<DOC>
	<DOCNO>NCT00825812</DOCNO>
	<brief_summary>The present trial set evaluate efficacy safety 2.0 mg.kg-1 sugammadex compare neostigmine administer reappearance T2 Chinese Caucasian subject registration purpose China .</brief_summary>
	<brief_title>Comparison 2.0 mg/kg Sugammadex Neostigmine Reappearance T2 Chinese European Subjects ( Study 19.4.324 ) ( P05768AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Subjects willing provide inform consent ; 18 64 year old ; American Society Anaesthesiology ( ASA ) class 13 ( extreme include ) ; schedule elective surgery general anesthesia , allow stable neuromuscular monitoring , require neuromuscular blockade use rocuronium ; compliant dose/visit schedule , use accept method contraception ( applicable ) . For China : Subjects Chinese descent bear China , never emigrate China Chinese home address . For Europe : Subjects Caucasian descent bear Europe , never emigrate Europe European home address . Subjects expect difficult intubation , neuromuscular disorder affect neuromuscular blockade , significant renal/hepatic dysfunction , use tourniquet , ( family ) history malignant hyperthermia , allergy general anesthesia medication , contraindication study drug , breast feeding , pregnant , participation previous new trial , clinically significant condition may interfere trial , membership ( family ) study/sponsor staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>